🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Gilead Sciences jumps on Lenacapavir data

Published 20/06/2024, 18:36
©  Reuters
GILD
-

Gilead Sciences (NASDAQ:GILD) shares surged 8% Thursday after the company announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial.

The company said the data indicates that its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in women.

PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada, Gilead said. They added that based on these results, the independent Data Monitoring Committee (DMC) recommended Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.

"With zero infections and 100% efficacy, twice-yearly lenacapavir has demonstrated its potential as an important new tool to help prevent HIV infections,” said Merdad Parsey, Chief Medical Officer, Gilead Sciences.

Following the news, analysts at Baird said they think lenacapavir's complete, 100% prevention of HIV infection during the 5,300-patient PURPOSE 1 study is an "impressive result and reflects the potential to become widely adopted as the PrEP treatment of choice, should it be approved."

"This should be supported by the Q6M dosing, which we view as improving the compliance concerns with QD orals," added the firm in a note. "This could be a sentiment booster to a stock that has otherwise seen sentiment sour over the last few years."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.